Beck Bode LLC reduced its position in Bristol-Myers Squibb Co (NYSE:BMY) by 6.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,017 shares of the biopharmaceutical company’s stock after selling 1,033 shares during the period. Beck Bode LLC’s holdings in Bristol-Myers Squibb were worth $762,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in BMY. Cypress Capital Management LLC boosted its stake in shares of Bristol-Myers Squibb by 21.2% during the 2nd quarter. Cypress Capital Management LLC now owns 154,335 shares of the biopharmaceutical company’s stock worth $6,999,000 after purchasing an additional 26,990 shares during the period. National Pension Service grew its stake in shares of Bristol-Myers Squibb by 6.0% during the second quarter. National Pension Service now owns 1,693,877 shares of the biopharmaceutical company’s stock valued at $76,817,000 after buying an additional 96,363 shares during the last quarter. Canada Pension Plan Investment Board raised its holdings in shares of Bristol-Myers Squibb by 9.3% in the second quarter. Canada Pension Plan Investment Board now owns 2,930,835 shares of the biopharmaceutical company’s stock worth $132,913,000 after buying an additional 248,935 shares during the period. Financial Advantage Inc. raised its holdings in shares of Bristol-Myers Squibb by 0.7% in the third quarter. Financial Advantage Inc. now owns 73,601 shares of the biopharmaceutical company’s stock worth $3,732,000 after buying an additional 487 shares during the period. Finally, Harborview Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb in the second quarter worth approximately $277,000. 83.01% of the stock is owned by institutional investors.
A number of equities analysts recently issued reports on BMY shares. Atlantic Securities upgraded Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 price objective for the company in a report on Wednesday, August 14th. ValuEngine upgraded Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a research report on Tuesday, November 19th. Wolfe Research set a $66.00 target price on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Friday, November 1st. TheStreet upgraded shares of Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a report on Wednesday, September 18th. Finally, Morgan Stanley started coverage on shares of Bristol-Myers Squibb in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $60.00 price target on the stock. One analyst has rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $57.95.
Shares of BMY traded up $0.04 during midday trading on Tuesday, reaching $57.45. 3,314,053 shares of the stock were exchanged, compared to its average volume of 24,667,110. Bristol-Myers Squibb Co has a 52 week low of $42.48 and a 52 week high of $59.17. The company has a current ratio of 3.83, a quick ratio of 3.72 and a debt-to-equity ratio of 1.37. The company’s 50 day moving average is $56.06 and its two-hundred day moving average is $49.44. The company has a market capitalization of $92.77 billion, a P/E ratio of 14.43, a PEG ratio of 1.32 and a beta of 0.70.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.17 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.06 by $0.11. Bristol-Myers Squibb had a net margin of 23.53% and a return on equity of 45.49%. The company had revenue of $6.01 billion during the quarter, compared to analyst estimates of $5.89 billion. During the same period in the prior year, the firm earned $1.09 earnings per share. The firm’s revenue for the quarter was up 5.6% compared to the same quarter last year. On average, sell-side analysts expect that Bristol-Myers Squibb Co will post 4.38 EPS for the current year.
In other Bristol-Myers Squibb news, SVP John E. Elicker sold 15,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.66, for a total transaction of $849,900.00. Following the completion of the sale, the senior vice president now owns 74,471 shares in the company, valued at $4,219,526.86. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Louis S. Schmukler sold 25,000 shares of the stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $56.56, for a total value of $1,414,000.00. Following the sale, the insider now directly owns 31,963 shares in the company, valued at approximately $1,807,827.28. The disclosure for this sale can be found here. Company insiders own 0.13% of the company’s stock.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Article: What impact do institutional investors have on markets?
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.